biostudies-literatureReader CSCRUK Core Facilities at Barts Cancer Institute, LondonCancer Research UKTraining FellowshipPancreatic Cancer UKMedical Research CouncilPancreatic Cancer Research FundWellcome Trust332-342https://www.ebi.ac.uk/biostudies/studies/S-EPMC6852434biostudies-literatureUnknown249(3)Pancreatic ductal adenocarcinoma (PDAC) has a 5-year survival rate of less than 4% and desperately needs novel effective therapeutics. Integrin αvβ6 has been linked with poor prognosis in cancer but its potential as a target in PDAC remains unclear. We report that transcriptional expression analysis revealed that high levels of β6 mRNA correlated strongly with significantly poorer survival (n = 491 cases, p = 3.17 × 10^-8 ). In two separate cohorts, we showed that over 80% of PDACs expressed αvβ6 protein and that paired metastases retained αvβ6 expression. In vitro, integrin αvβ6 promoted PDAC cell growth, survival, migration, and invasion. Treatment of both αvβ6-positive human PDAC xenografts and transgenic mice bearing αvβ6-positive PDAC with the αvβ6 blocking antibody 264RAD, The Journal of pathologyThe integrin αvβ6 drives pancreatic cancer through diverse mechanisms and represents an effective target for therapy.PMC685243423526RIF2015_A06_JAMIESON1776429996G0800825FLF2015_04_GLASGOW25233103721/Z/14/Z1165020409C16420/A1806621139Chelala CMarshall JFKeyse SMReader CSMoore KMSansom OJBrentnall ALawlor RVallath SBarry STDesai AScarpa AEvans TJHaider SChang DJamieson NBBiankin AMorton JPKocher HMSteele CWBailey PfalseThe integrin αvβ6 drives pancreatic cancer through diverse mechanisms and represents an effective target for therapy.Pancreatic ductal adenocarcinoma (PDAC) has a 5-year survival rate of less than 4% and desperately needs novel effective therapeutics. Integrin αvβ6 has been linked with poor prognosis in cancer but its potential as a target in PDAC remains unclear. We report that transcriptional expression analysis revealed that high levels of β6 mRNA correlated strongly with significantly poorer survival (n = 491 cases, p = 3.17 × 10^-8 ). In two separate cohorts, we showed that over 80% of PDACs expressed αvβ6 protein and that paired metastases retained αvβ6 expression. In vitro, integrin αvβ6 promoted PDAC cell growth, survival, migration, and invasion. Treatment of both αvβ6-positive human PDAC xenografts and transgenic mice bearing αvβ6-positive PDAC with the αvβ6 blocking antibody 264RAD, 2019-01-01T00:00:00Z2019 Nov2025-04-04T08:26:57.767Z2020-05-21T19:10:47ZS-EPMC68524343125942210.1002/path.5320